Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

Reference:

Stone, M. A., Payne, U., Pacheco-Tena, C. and Inman, R. D., 2004. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Annals of the Rheumatic Diseases, 63 (1), pp. 84-87.

Related documents:

Abstract

Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p

Export

Actions (login required)